The incidence of secondary myelodysplastic syndromes and acute leukemia (MDS/AL) was reported for 395 patients autografted for Hodgkin's disease (HD) (n = 96) and non-Hodgkin's lymphoma (NHL) (n = 299) between 1987 and 1998. Eleven patients developed secondary MDS/AL (crude rate at 2.8%) including two lymphoblastic AL cases. The mean time of occurrence was at 32 months after autologous stem cell transplantation (ASCT) and 71 months after diagnosis. The estimated actuarial incidence at 10 years was at 6.3% (±4%). Karyotyping revealed complex chromosomal aberrations in only one patient, and two translocations [t(8;21) and t(8;16)]. No features of topoisomerase II inhibitorrelated leukemia were found. Only one patient had received ASCT in first remission. The remaining 10 patients had received multiple courses of chemotherapy before stem cell collection and four had relapsed after ASCT and before the occurrence of secondary MDS/AL. Five of 11 patients had received localized radiotherapy and five others received TBI in their conditioning regimen. Ten patients died despite chemotherapy and/or supportive care and only one patient is alive and well after genoidentical allogeneic transplantation. We suggest a cumulative leukemogenic role of pre-ASCT radiation and chemotherapy in the occurrence of these secondary MDS/AL more than the highdose therapy itself. Bone Marrow Transplantation (2000) 26, 321-326. Keywords: chemotherapy; acute leukemia; myelodysplasia; autologous stem cell transplantation; lymphoma Therapeutic intensification with autologous stem cell transplantation (ASCT) has been widely used in the past 10 years for treating lymphomas. These intensified therapies have increased response rates to chemotherapy and have shown a benefit in survival in some randomised studies.
Therapeutic intensification with autologous stem cell transplantation (ASCT) has been widely used in the past 10 years for treating lymphomas. These intensified therapies have increased response rates to chemotherapy and have shown a benefit in survival in some randomised studies. 1, 2 However, these good results may be tempered by the risk of second malignancies reported in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) patients receiving high doses of alkylating agents and radiation therapy for treatment, especially secondary MDS/AL. [3] [4] [5] It has been established that secondary MDS/AL occurs after mutagenic drugs, radiation and environmental exposure, 3 thus it is to be expected that intensive chemo/radiotherapy could be an additional risk factor. Some reports with conventional chemotherapy have shown an increased risk of secondary MDS/AL after ASCT for HD with a crude incidence of 7.6% and an actuarial risk at 6 years up to 18 ± 9%. 4 In this later study the most important risk factor for secondary MDS/AL was sustained bone marrow stem cell damage before the transplantation. Here, we report the features of 11 cases of secondary MDS/AL among 395 adult patients who received ASCT for lymphoid malignancies. This represents a review of a single-institution experience over 11 years.
Patients and methods

Patients
Between 1987 and 1998, 395 patients underwent 423 highdose therapies and ASCT for NHL (low-grade, n = 88; intermediate-grade, n = 164; high-grade, n = 47) or HD (n = 96). Three hundred and sixty-seven patients had one autotransplant, 24 patients received a tandem ASCT and four patients received a second ASCT after relapse from the first one. At the time of autotransplantation, they were aged between 11 and 69 years old (median age: 40 years). The major indications for autograft were: first relapse for HD and NHL (n = 198) or further relapse (n = 41), primary refractory disease (n = 36) and first-line consolidation in high risk lymphoma (eg lymphoblastic lymphoma or aggressive lymphoma and IPI Ͼ2 6 or partial responders) (n = 120). Before 1992, patients who were given high-dose therapy and ASCT received bone marrow or chemotherapymobilized peripheral blood progenitor cells (PBPC) whereas after 1992, they mostly received chemotherapy and granulocyte colony-stimulating factor (G-CSF)-mobilized PBPC except when leukaphereses failed. 7 The stem cell source was not purged apart from 24 cases whose PBPC underwent a CD34-positive cell selection. Patients with leukemic involvement from NHL after autotransplantation (eg lymphoblastic or Burkitt or B-centroblastic large cell) were considered as relapses and not secondary MDS/AL. With a median follow up of 3 years, considering the entire popu-lation, the estimated 10 year actuarial survival is 58 ± 6% and the rate of toxic death is 4%.
Methods
Date of diagnosis and type of secondary MDS/AL were reported. Cytology and cytogenetics when available were reviewed in 10 cases. For each patient, age at autotransplantation, interval between lymphoma diagnosis and ASCT, type of chemotherapy (caryolysine, fludarabine, etoposide) or radiation and the number of regimens and courses received before ASCT, conditioning regimen, type of stem cell source and use or non-use of hematopoietic growth factors were ascertained.
Statistics
The primary endpoint for the analysis was the diagnosis of MDS/AL made before the stopping date (1 April 1999). Time to diagnosis of MDS/AL was measured from date of ASCT for lymphoma to the date of diagnosis of MDS/AL on bone marrow aspiration. Patients who did not develop MDS/AL were censored at death or at the date last known alive. The Kaplan-Meier method was used to assess the cumulative and actuarial incidence of MDS/AL. 
Results
During this period, 11 patients were diagnosed with secondary MDS/AL between 6 and 60 months post ASCT which represents a crude incidence of 2.8% and a cumulative incidence of 4%. The actuarial incidence was estimated at 6.3% (±4%) (Figure 1 ).
Clinical characteristics
Characteristics of patients with secondary MDS/AL are listed in Table 1 . Sixty-three percent of the patients initially had a NHL. The median interval between diagnosis and autotransplantation was 32 months (5-120 months) and one patient had two autotransplants. The median interval between diagnosis and occurrence of secondary MDS/AL was 71 months (24-156 months). Five patients out of 11 received bone marrow as the source of stem cells and six received a PBPC transplant (only one patient had a CD34-positive cell selection). Eight patients had received G-CSF post ASCT to hasten neutrophil recovery. Hematologic recovery after ASCT was good with a median number of days to reach a WBC count Ͼ0.5 × 10 9 /l of 16 and to reach a platelet count Ͼ50 × 10 9 /l of 23. A normal blood count was observed within 3 months. Immune system abnormalities comprised four patients with hypogammaglobulinemia (Ͻ4 g/l), and two with a monoclonal IgM peak. The two patients who were diagnosed B ALL had B cell low-grade lymphoma (follicular (FCL) and small lymphocytic lymphoma (SLL)). They received high-dose therapy with total body irradiation and ASCT, respectively, for their first and second relapse. The diagnosis of B ALL was made without relapse of SLL for UPN 11 and after relapse of FCL for UPN 10. In these two cases the possibility of a transformation of the primitive B cell malignancy cannot be excluded.
Hemato-cytology and cytogenetics (Table 2)
At diagnosis of secondary MDS/AL, patients had a mean hemoglobin level of 8.75 g/dl (range 7-11.5), a mean platelet count of 46 × Dysgranulopoiesis was the major feature of secondary MDS/AL. Abnormalities of the thrombopoietic lineage were also noted. According to the FAB classification, there was one refractory anemia, two refractory anemias with excess of blasts, six AML (AML2 with t(8;21) n = 1, AML6 with t(8;16) n = 1, AML7 with complex karyotype including del(7) n = 1 and three undetermined secondary AML) and two cases of secondary B cell ALL. Only one patient presented with AML2 with t(8;21) and no cytological features of secondary leukemia.
Previous treatment
Before PBPC collection, patients in relapse (n = 6) received an average number of six cycles of second-line chemotherapy. For patients who had refractory disease (n = 3), between two and three lines of chemotherapy were administered before PBPC collection. Only one patient had received a single line of chemotherapy before the cytaphereses.
Prior radiotherapy: five patients were irradiated to 12 Gy fractionated or 10 Gy single-dose total body irradiation (TBI) in the conditioning regimen. Five other patients had received radiation therapy for relapse before high-dose therapy and ASCT (n = 4) or after relapse post ASCT (n = 1) (30 Gy to the vertebral body, 18 Gy to the central nervous system, 40 Gy as inverted Y, 20 Gy as total nodal irradiation, and 40 Gy to the hip). Only one patient (UPN 4) had never received radiation therapy. He presented with AML2 early after ASCT and died from both lymphoma relapse and leukemia. The number of chemotherapy lines given before ASCT are listed in Table 1 and the mean num- Status at the time of autotransplantation. b Delay between ASCT and MDS/AL. CT = chemotherapy; RT = radiation therapy; ASCT = autologous stem cell transplantation; GCSF = granulocyte colony-stimulating factor; MDS/AL = type of secondary leukemia; F = female; M = male; FCL = follicle center lymphoma; HD = Hodgkin's disease; DLBL = diffuse large B cell lymphoma; LBL = lymphoblastic lymphoma; MCL = mantle cell lymphoma; SLL = small lymphocytic lymphoma; Y = yes; N = no; BM = bone marrow; PBPC = peripheral blood progenitors cells; CBV = cyclophosphamide, carmustine, etoposide; BEAM = carmustine, etoposide, cytarabine, melphalan; BEAC = carmustine, etoposide, cytarabine, cyclophosphamide; TEC = total body irradiation, etoposide, cyclophosphamide; RA(EB) = refractory anemia (with excess blasts); sAML = secondary acute myeloid leukemia; ALL = acute lymphoblastic leukemia. Bone Marrow Transplantation received etoposide in their salvage chemotherapy at the dose of 300-450 mg/m 2 for two to four cycles. No features of topoisomerase II inhibitor-related leukemia were found in our study group. Three patients had received fludarabine therapy and only one patient with HD had received caryolysine (MOPP, 14 cycles) before PBPC collection. In Table  3 we describe the characteristics of the 11 patients with secondary MDS/AL compared to those of the 395 patients grafted for NHL and HD over the same period. We observed that secondary MDS/AL occurred more frequently in heavily pretreated patients (relapse Ͼ1), refractory disease and after TBI in the conditioning regimen.
Outcome
After diagnosis of secondary MDS/AL, five patients received only supportive treatment with transfusions and antibiotics and six patients received chemotherapy (Table  2 ) (four AML and two ALL). Remission was achieved in three of six patients treated with chemotherapy and early relapse occurred in two patients who died from leukemia. Overall, 10 patients died from secondary MDS/AL (91%) which represented a death rate of 2% from secondary MDS/AL in all patients who had received high-dose therapy and ASCT. The only living patient with 6 years followup (UPN 3) received a genoidentical allogeneic transplant after chemotherapy-induced remission of their secondary AML.
Discussion
Intensive chemotherapy with ASCT has improved survival of patients with chemosensitive relapse from HD 1 and NHL. 2 With longer follow-up, late effects of these intensive chemo/radiotherapies have been observed and consist mainly of secondary MDS/AL. They appeared at a median of 5 years after transplantation. 9 Here, we report 11 cases of secondary MDS/AL (including two ALL) in a population of 395 patients receiving ASCT for lymphoid malignancies at the same center. These cases represented a cumulative incidence of 4%. This rate was similar to that of Toronto's team who reported 10 cases of secondary malignancies among 557 grafted patients. 10 Secondary MDS/AL have been observed after ASCT for HD with a 5-year cumulative incidence of 4% in a population of 393 grafted patients. 11 However, our rate of secondary MDS/AL was lower than that observed by the Minneapolis group, but that later study included 206 patients over a period of 19 years as opposed to 11 years, as in our study. 12 Our median follow-up is 36 months and we are aware that with a longer follow-up the incidence of secondary MDS/AL may increase slightly. The risk of secondary MDS/AL has been extensively studied in longterm survivors of HD and has been estimated to be from 2 to 5% at a median of 60 months. 13 The early occurrence of secondary MDS/AL after ASCT observed in our series (32 months) suggests that the previous treatment is more likely to have induced bone marrow damage than the conditioning regimen of ASCT itself.
All patients but one had received radiotherapy (TBI in the conditioning regimen or localized radiotherapy). Previous treatment with radiation was a feature observed in other series of secondary MDS/AL. 14, 15 Only one patient had never received radiotherapy during his disease course. In HD at least, radiation therapy associated with MOPP chemotherapy has been correlated with a higher risk of secondary leukemia, especially if it was with extensive fields. 13 In a univariate analysis, Toronto's team showed that TBI was linked to the development of secondary neoplasms. 10 In stage II-IV NHL, TBI was associated with two major complications: thrombocythaemia and late myeloproliferative disorders.
14 However, with doses of TBI of 10 Gy, Carbonell et al 16 studied cytogenetic aberrations in the bone marrow and peripheral lymphocytes from treated patients and found that despite DNA damage, the cells were able to recover from this physical aggression. The high-dose chemotherapy given before and with the TBI may have increased the risk and this association has been reported to cause secondary MDS/AL in pediatric patients treated for rhabdomyosarcomas, NHL and HD. 17, 18 A recent study of NHL patients receiving TBI in their conditioning regimen found an actuarial incidence at 10 years of 19.8%. 19 The second main factor associated with the occurrence of myelodysplastic syndromes was the chemotherapy given prior to PBPC collection. Our study patients received a median of six cycles of chemotherapy before PBPC collection. The number of courses of MOPP has been shown to be a prognostic factor for increased risk of secondary MDS/AL in HD patients, 20, 21 but MOPP chemotherapy has not been so widely used in the past 15 years in our center. Etoposide, a topoisomerase II inhibitor used in most conditioning regimens, has also been found to be leukemogenic. Ten acute leukemias occurred in a casecontrol study of secondary MDS/AL in survivors of childhood cancer diagnosed in the UK between 1940 and 1983. 22 The relative risk of secondary MDS/AL rose with increasing exposure to epipodophyllotoxin, and this remained after controlling for exposure to other cytotoxic drugs and average dose of irradiation to the patients' bone marrow. 23 A particular cytogenetic characteristic was 11q23 translocation. In our study, no patients had features of topoisomerase II inhibitor-related leukemia but they had received lower dose of etoposide than in other series. Fludarabine, a purine analogue, has also been incriminated in the occurrence of secondary neoplasms 24 and three of our patients had received a median number of 5.6 cycles of fludarabine. After autotransplantation, the immune system is impaired for at least 1-3 months because chemoradiotherapy ablates normal and abnormal immunohematopoietic cells. 25 The absolute lymphocyte and B cell count returned to the normal range within 1-3 months after grafting, but the Ig range reached its normal rate only 1 year later and the number of CD4 T lymphocytes remained low for up to 2 years after ASCT. This defect in regulating T cells may have favored the occurrence of second neoplasms. On the other hand, hematopoietic growth factor used for the mobilization of PBPC may have induced morphological changes of marrow and peripheral blood circulating cells. 26 Several studies have shown that hematopoietic growth factor does not induce a higher rate of mortality because of secondary malignancies.
What do these post-transplant patients with myelodysplastic syndrome really have? In most cases, they certainly have a clonal malignancy arising as a consequence of stem cell damage prior to the conditioning regimen. Most previous studies of secondary MDS/AL after ASCT have focused on the pretransplant therapy, rather than the myeloablative regimen as a risk factor. 27 Secondary MDS/AL rarely develop after allogeneic transplantation, suggesting that they develop from autologous cells accumulating mutations because of subablative prior chemotherapy. 28 Time from the initial treatment to the secondary MDS/AL development, prolonged exposure to alkylating agents and repeated radiotherapy exposure are all probably implicated. In conclusion, for a particular group of lymphoma patients, high-dose therapy with ASCT remains the treatment of choice and the occurrence of secondary MDS/AL should be monitored carefully with a longer follow-up.
